{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-005254","form_type":"8-K","ticker":"NNVC","cik":"0001379006","company_name":"NANOVIRICIDES, INC.","filed_at":"2024-01-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.003025+00:00","generated_at":"2026-06-06T21:10:50.540852+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"confidence":"high","headline":"NanoViricides shareholders re-elect Anil Diwan as director, approve executive compensation and preferred stock grant","bullets":["At the January 13, 2024 annual meeting, shareholders re-elected Anil Diwan as Class I director with 5,590,467 votes for, 308,092 against, 488,175 abstentions, and 3,056,966 broker non-votes.","An advisory vote on named executive officer compensation passed with 5,572,378 votes for and 788,423 against, plus 3,056,966 broker non-votes.","Approval of a grant of 10,204 Series A Convertible Preferred Shares to Anil Diwan in connection with his employment extension passed with 5,508,079 votes for, 844,079 against.","Ratification of EisnerAmper LLP as independent registered public accounting firm for fiscal year ending June 30, 2024 passed with 9,165,259 votes for, 152,847 against."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-005254","json":"https://secwatch.observer/filing/0001104659-24-005254.json","markdown":"https://secwatch.observer/filing/0001104659-24-005254.md","text":"https://secwatch.observer/filing/0001104659-24-005254.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1379006/000110465924005254/0001104659-24-005254-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1379006/000110465924005254/tm243719d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T21:10:50.540852+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1be380719794af1da2c7471d4bd3c11529198283","claim":"NANOVIRICIDES, INC. shareholders approved Advisory vote on the compensation of the Company’s named executive officers at the 2024-01-13 meeting.","evidence_excerpt":"Proposal 2 – Advisory Vote on Compensation of Named Executive Officers: Votes For Votes Against Votes Abstained Broker Non-Votes 5,572,378 788,423 25,933 3,056,966","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1379006/000110465924005254/0001104659-24-005254-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-01-13"}],"fact_type":"shareholder_vote"},{"claim_id":"3f4b11219029bcd52deb1516c85d972f928f4974","claim":"NANOVIRICIDES, INC. shareholders approved Approval of an award of 10,204 Series A Preferred Shares to Anil Diwan in connection with the extension of his employment as the Company’s President at the 2024-01-13 meeting.","evidence_excerpt":"Proposal 3 – Approval of Convertible Preferred Stock Grant to Anil Diwan: Votes For Votes Against Votes Abstained Broker Non-Votes 5,508,046 844,079 34,609 3,056,966","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1379006/000110465924005254/0001104659-24-005254-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-01-13"}],"fact_type":"shareholder_vote"},{"claim_id":"975b71a7d233d89e8ba40b068e45a53e1df91af9","claim":"NANOVIRICIDES, INC. shareholders approved Re-election of Anil Diwan as a Class I Director for a two-year term expiring at the 2025 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier resignation or removal at the 2024-01-13 meeting.","evidence_excerpt":"Proposal 1 – Election of Director - Re-Election of Anil Diwan as a Class I Director: Votes For Votes Against Votes Abstained Broker Non-Votes 5,590,467 308,092 488,175 3,056,966","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1379006/000110465924005254/0001104659-24-005254-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-01-13"}],"fact_type":"shareholder_vote"},{"claim_id":"b149cc5ffa3d2e8614fb5fcd657fb0b6df7681cb","claim":"NANOVIRICIDES, INC. shareholders approved Ratification of the appointment of EisnerAmper, LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2024 at the 2024-01-13 meeting.","evidence_excerpt":"Proposal 4 – To ratify the appointment of EisnerAmper, LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2024: Votes For Votes Against Votes Abstained 9,165,259 152,847 125,594","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1379006/000110465924005254/0001104659-24-005254-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-01-13"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}